Presentation and management of docetaxel-related adverse effects in patients with breast cancer

References

• BerryDACroninKAPlevritisSKEffect of screening and adjuvant therapy on mortality from breast cancerN Engl J Med2005353171784179216251534
   PubMed Web of Science ®Google Scholar
• HowladerNNooneAMKrapchoMThe Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975–2008National Cancer InstituteBethesda, MD2010 Available from: http://seer.cancer.gov/csr/1975_2008/index.htmlAccessed May 10, 2014
   Google Scholar
• van der HageJAMieogJSvan de VeldeCJPutterHBartelinkHvan de VijverMJImpact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trialsBreast Cancer Res2011133R6821699739
   PubMed Web of Science ®Google Scholar
• AlbainKSBarlowWEShakSPrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialLancet Oncol2010111556520005174
   PubMed Web of Science ®Google Scholar
• PetoRDaviesCGodwinJEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet2012379981443244422152853
   PubMed Web of Science ®Google Scholar
• MackeyJRMartinMPienkowskiTAdjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the Phase 3 randomised BCIRG 001 trialLancet Oncol2013141728023246022
   PubMed Web of Science ®Google Scholar
• MartinMPienkowskiTMackeyJAdjuvant docetaxel for node-positive breast cancerN Engl J Med2005352222302231315930421
   PubMed Web of Science ®Google Scholar
• SwainSMLandSRRitterMWAmenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialBreast Cancer Res Treat2009113231532018302020
   PubMed Web of Science ®Google Scholar
• JonesSHolmesFAO’ShaughnessyJDocetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735J Clin Oncol20092781177118319204201
   PubMed Web of Science ®Google Scholar
• JonesSESavinMAHolmesFAPhase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerJ Clin Oncol200624345381538717135639
   PubMed Web of Science ®Google Scholar
• CoudertBAsselainBCamponeMExtended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trialOncologist201217790090922610153
   PubMed Web of Science ®Google Scholar
• EiermannWPienkowskiTCrownJPhase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialJ Clin Oncol201129293877388421911726
   PubMed Web of Science ®Google Scholar
• RocheHFumoleauPSpielmannMSequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialJ Clin Oncol200624365664567117116941
   PubMed Web of Science ®Google Scholar
• SparanoJAWangMMartinoSWeekly paclitaxel in the adjuvant treatment of breast cancerN Engl J Med2008358161663167118420499
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• HeysSDHutcheonAWSarkarTKNeoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trialClin Breast Cancer20023Suppl 2S69S7412435290
   PubMedGoogle Scholar
• SmithICHeysSDHutcheonAWNeoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxelJ Clin Oncol20022061456146611896092
   PubMed Web of Science ®Google Scholar
• NabholtzJMFalksonCCamposDDocetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trialJ Clin Oncol200321696897512637459
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJBurzykowskiTBuyseMTaxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancerJ Clin Oncol200826121980198618421049
   PubMed Web of Science ®Google Scholar
• RavdinPMBurrisHA3rdCookGPhase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancerJ Clin Oncol19951312287928858523050
   PubMed Web of Science ®Google Scholar
• ChiaSKSpeersCHD’YachkovaYThe impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancerCancer2007110597397917647245
   PubMed Web of Science ®Google Scholar
• WilckenNHornbuckleJGhersiDChemotherapy alone versus endocrine therapy alone for metastatic breast cancerCochrane Database Syst Rev20032CD00274712804433
   PubMed Web of Science ®Google Scholar
• ChanSFriedrichsKNoelDProspective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancerJ Clin Oncol19991782341235410561296
   PubMed Web of Science ®Google Scholar
• VermaSMaraninchiDO’ShaughnessyJCapecitabine plus docetaxel combination therapyCancer2005103122455246515892043
   PubMed Web of Science ®Google Scholar
• PegramMDKonecnyGEO’CallaghanCBerytMPietrasRSlamonDJRational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancerJ Natl Cancer Inst2004961073974915150302
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• ValeroVForbesJPegramMDMulticenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensJ Clin Oncol201129214915621115860
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• SchroderCPde MunckLWestermannAMWeekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxelEur J Cancer20114791355136221251813
   PubMed Web of Science ®Google Scholar
• StemmlerHJHarbeckNGroll de RiveraIProspective multicenter randomized Phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancerOncology2010793–419720321358207
   PubMed Web of Science ®Google Scholar
• SyrigouEDannosIKotteasEHypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocolInt Arch Allergy Immunol2011156332032421720178
   PubMed Web of Science ®Google Scholar
• SchrijversDWandersJDirixLCoping with toxicities of docetaxel (Taxotere)Ann Oncol81993476106118103352
   PubMed Web of Science ®Google Scholar
• WangGSYangKYPerngRPLife-threatening hypersensitivity pneumonitis induced by docetaxel (Taxotere)Br J Cancer20018591247125011720456
   PubMed Web of Science ®Google Scholar
• ArdavanisATryfonopoulosDYiotisIGerasimidisGBaziotisNRigatosGNon-allergic nature of docetaxel-induced acute hypersensitivity reactionsAnticancer Drugs200415658158515205600
   PubMed Web of Science ®Google Scholar
• EschalierALavarenneJBurtinCRenouxMChapuyERodriguezMStudy of histamine release induced by acute administration of antitumor agents in dogsCancer Chemother Pharmacol19882132462502452032
   PubMed Web of Science ®Google Scholar
• FossellaFVLeeJSMurphyWKPhase II study of docetaxel for recurrent or metastatic non-small-cell lung cancerJ Clin Oncol1994126123812447911160
   PubMed Web of Science ®Google Scholar
• SzebeniJMuggiaFMAlvingCRComplement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro studyJ Natl Cancer Inst19989043003069486816
   PubMedGoogle Scholar
• WeissRBDonehowerRCWiernikPHHypersensitivity reactions from taxolJ Clin Oncol199087126312681972736
   PubMed Web of Science ®Google Scholar
• FreifeldAGBowEJSepkowitzKAClinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of AmericaClin Infect Dis201152442743121205990
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical practice guidelines in oncology (NCCN Guidelines)Breast Cancer. Version 12014 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast
   Google Scholar
• AaproMSBohliusJCameronDA2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEur J Cancer201147183221095116
   PubMed Web of Science ®Google Scholar
• AartsMJPetersFPMandigersCMPrimary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropeniaJ Clin Oncol201331344290429623630211
   PubMed Web of Science ®Google Scholar
• MartinMLluchASeguiMAToxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimenAnn Oncol20061781205121216766587
   PubMed Web of Science ®Google Scholar
• SmithTJKhatcheressianJLymanGH2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineJ Clin Oncol200624193187320516682719
   PubMed Web of Science ®Google Scholar
• SembKAAamdalSOianPCapillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatmentJ Clin Oncol19981610342634329779722
   PubMed Web of Science ®Google Scholar
• PiccartMJKlijnJParidaensRCorticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast CancerJ Clin Oncol1997159314931559294478
   PubMed Web of Science ®Google Scholar
• ChouhanJDHerringtonJDSingle premedication dose of dexamethasone 20 mg IV before docetaxel administrationJ Oncol Pharm Pract201117315515920447949
   PubMedGoogle Scholar
• MontoyaMEMarkowitzABKlementichFPalacioDDocetaxel and fluid retention: use of single-dose dexamethasoneJ Clin Oncol20072518S19635
   Google Scholar
• SingerEASrinivasanRIntravenous therapies for castration-resistant prostate cancer: toxicities and adverse eventsUrol Oncol201230Suppl 4S15S1922014836
   PubMed Web of Science ®Google Scholar
• EichDScharffetter-KochanekKEichHTTantcheva-PoorIKriegTAcral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancerAm J Clin Oncol200225659960212478008
   PubMed Web of Science ®Google Scholar
• ChewLChuenVSCutaneous reaction associated with weekly docetaxel administrationJ Oncol Pharm Pract2009151293418753180
   PubMedGoogle Scholar
• ChuCYYangCHYangCYHsiaoGHChiuHCFixed erythrodysaesthesia plaque due to intravenous injection of docetaxelBr J Dermatol2000142480881110792238
   PubMed Web of Science ®Google Scholar
• CanGAydinerACavdarITaxane-induced nail changes: predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicityEur J Oncol Nurs201216327027521784705
   PubMed Web of Science ®Google Scholar
• ScotteFTouraniJMBanuEMulticenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the handJ Clin Oncol200523194424442915994152
   PubMed Web of Science ®Google Scholar
• OchoaRBejaranoPAGluckSMonteroAJPneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature reviewJ Med Case Rep20126141323198815
   PubMedGoogle Scholar
• HarveyVMouridsenHSemiglazovVPhase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancerJ Clin Oncol200624314963497017033039
   PubMed Web of Science ®Google Scholar
• ChenYMShihJFPerngRPTsaiCMWhang-PengJA randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapyChest200612941031103816608954
   PubMed Web of Science ®Google Scholar
• KatakamiNTakiguchiYYoshimoriKDocetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized Phase II study by the Japan Lung Cancer Cooperative Clinical Study GroupJ Thorac Oncol20061544745317409898
   PubMed Web of Science ®Google Scholar
• NakamuraMKoizumiTHayasakaMCisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancerCancer Chemother Pharmacol20096361091109618818921
   PubMed Web of Science ®Google Scholar
• OnishiHKuriyamaKYamaguchiMConcurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitisLung Cancer2003401798412660011
   PubMed Web of Science ®Google Scholar
• TamiyaANaitoTMiuraSInterstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancerAnticancer Res20123231103110622399640
   PubMed Web of Science ®Google Scholar
• CourneyaKSSegalRJMackeyJREffects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trialJ Clin Oncol200725284396440417785708
   PubMed Web of Science ®Google Scholar
• MongaUGarberSLThornbyJExercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapyArch Phys Med Rehabil200788111416142217964881
   PubMed Web of Science ®Google Scholar
• ChanASuCde BoerRHGajdatsyAPrevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapyJ Clin Oncol201331172123212723650421
   PubMed Web of Science ®Google Scholar
• EsmaeliBAminSValeroVProspective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxelJ Clin Oncol200624223619362216877729
   PubMed Web of Science ®Google Scholar
• EsmaeliBValeroVEpiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important?J Clin Oncol201331172076207723650413
   PubMed Web of Science ®Google Scholar
• BremerCTMonahanBPNecrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearnedCurr Gastroenterol Rep20068433334116836946
   PubMedGoogle Scholar
• DavilaMLNeutropenic enterocolitisCurr Opin Gastroenterol2006221444716319675
   PubMed Web of Science ®Google Scholar
• LeeJJSwainSMPeripheral neuropathy induced by microtubule-stabilizing agentsJ Clin Oncol200624101633164216575015
   PubMed Web of Science ®Google Scholar
• RiveraEMejiaJAArunBKPhase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancerCancer200811271455146118300256
   PubMed Web of Science ®Google Scholar
• JonesSEErbanJOvermoyerBRandomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancerJ Clin Oncol200523245542555116110015
   PubMed Web of Science ®Google Scholar
• RaoRDMichalakJCSloanJAEfficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a Phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)Cancer200711092110211817853395
   PubMed Web of Science ®Google Scholar